Natera
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 3K
- Market Cap
- -
- Website
- http://www.natera.com
- Introduction
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
- Conditions
- Colo-rectal Cancer
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 25000
- Registration Number
- NCT07046585
- Locations
- 🇺🇸
Natera, Inc, Austin, Texas, United States
EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND)
- Conditions
- Single Gene NIPT
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 4000
- Registration Number
- NCT06808880
- Locations
- 🇺🇸
Valley Perinatal, Glendale, Arizona, United States
🇺🇸Cedars Sinai Prenatal Diagnosis Center, Los Angeles, California, United States
🇺🇸Center for Fetal Medicine and Womens Ultrasound, Los Angeles, California, United States
Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection
- Conditions
- Colorectal Cancer Screening
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 5000
- Registration Number
- NCT06620627
- Locations
- 🇺🇸
Natera, Austin, Texas, United States
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
- Conditions
- Heart Transplant Failure and Rejection
- Interventions
- Diagnostic Test: The Prospera™ Test
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT06414603
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
Renasight Clinical Application, Review and Evaluation (RenaCARE) Study
- Conditions
- Kidney Diseases
- Interventions
- Diagnostic Test: Renasight
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 1720
- Registration Number
- NCT05846113
- Locations
- 🇺🇸
Liberty Dialysis/US Renal Care (USRC), Anchorage, Alaska, United States
🇺🇸AKDHC Medical Research Services, LLC (Arizona Kidney Disease & Hypertension Centers), Tucson, Arizona, United States
🇺🇸Renal Consultants Medical Group (USRC), Granada Hills, California, United States
Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management.
- Conditions
- Pregnancy ComplicationsMultiple Gestation; Maternal CareTwin to Twin Transfusion Syndrome
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT05312814
- Locations
- 🇺🇸
Rady Children Specialists of San Diego, San Diego Perinatal Center, San Diego, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Anne Arundel Medical Center/Luminis Health, Annapolis, Maryland, United States
Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation
- Conditions
- Heart Transplant
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT05309382
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
Prospera Test Evaluation in Cardiac Transplant (ProTECT)
- Conditions
- Heart Transplant Rejection
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 411
- Registration Number
- NCT05205551
- Locations
- 🇺🇸
Natera, San Carlos, California, United States
LAMBDA 002 (Lung Registry) Study
- Conditions
- Lung Transplant Rejection
- Interventions
- Device: Prospera
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Natera, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT05170425
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, California City, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
- Conditions
- Heart Transplant Failure and Rejection
- Interventions
- Procedure: Endomyocardial biopsyDiagnostic Test: Prospera Transplant Assessment
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Natera, Inc.
- Registration Number
- NCT05081739